Sector News

Fredrik Wetterlundh joins Sobi™ as head of human resources

April 4, 2018
Life sciences

Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Fredrik Wetterlundh as Head of Human Resources. Fredrik will join Sobi on 9 April 2018 and be part of Sobi’s Extended Leadership Team.

Fredrik Wetterlundh joins Sobi from Pfizer, where he held the position of Global Human Resources Lead in Pfizer’s Global Supply organisation. He has extensive international experience in leading business-driven HR organisations, processes and projects in Asia, Europe, and North and Central America, and has supported a number of successful mergers and acquisitions and divestitures. Fredrik holds a degree in HR Management from the University of Lund, Sweden.

Guido Oelkers, CEO and President of Sobi, sees the appointment as a valuable addition to the company. “His experience from the pharmaceutical industry, numerous company integrations and the global roles he has held will be of great value for Sobi, supporting our organisation and our journey to become a global leader in rare diseases,” he said.

Fredrik says he is excited to be joining Sobi. “Sobi is a value-driven company with highly experienced employees and a strong culture. These are valuable assets to build on. I look forward to contributing to Sobi’s growth strategy with my experience in implementing effective organisation and people strategies,” he said.

Source: Sobi™

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach